Success Metrics

Clinical Success Rate
75.6%

Based on 31 completed trials

Completion Rate
76%(31/41)
Active Trials
3(4%)
Results Posted
45%(14 trials)
Terminated
10(15%)

Phase Distribution

Ph early_phase_1
1
1%
Ph phase_2
33
49%
Ph not_applicable
8
12%
Ph phase_1
7
10%
Ph phase_3
11
16%

Phase Distribution

8

Early Stage

33

Mid Stage

11

Late Stage

Phase Distribution60 total trials
Early Phase 1First-in-human
1(1.7%)
Phase 1Safety & dosage
7(11.7%)
Phase 2Efficacy & side effects
33(55.0%)
Phase 3Large-scale testing
11(18.3%)
N/ANon-phased studies
8(13.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

70.5%

31 of 44 finished

Non-Completion Rate

29.5%

13 ended early

Currently Active

3

trials recruiting

Total Trials

67

all time

Status Distribution
Active(3)
Completed(31)
Terminated(13)
Other(20)

Detailed Status

Completed31
unknown20
Terminated10
Withdrawn3
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
67
Active
3
Success Rate
75.6%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (1.7%)
Phase 17 (11.7%)
Phase 233 (55.0%)
Phase 311 (18.3%)
N/A8 (13.3%)

Trials by Status

completed3146%
unknown2030%
withdrawn34%
recruiting34%
terminated1015%

Recent Activity

3 active trials
Showing 5 of 67
completedphase_3

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

NCT04376034
recruitingphase_3

Randomised Evaluation of COVID-19 Therapy

NCT04381936
completednot_applicable

Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection

NCT04408209
completedphase_2

Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation

NCT04558476
terminatedphase_2

Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

NCT04513158
View all 67 trials

Clinical Trials (67)

Showing 20 of 67 trialsScroll for more
NCT04376034Phase 3

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

Completed
NCT04381936Phase 3

Randomised Evaluation of COVID-19 Therapy

Recruiting
NCT04408209Not Applicable

Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection

Completed
NCT04558476Phase 2

Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation

Completed
NCT04513158Phase 2

Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

Terminated
NCT02735707Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
NCT05077930Phase 2

Convalescent Plasma Therapy for Hospitalized Patients With COVID-19

Completed
NCT06084351Phase 3

Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection

Withdrawn
NCT04456413Phase 2

Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection

Terminated
NCT04343755Phase 2

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

Terminated
NCT05157165

Convalescent Plasma in Hospitalized COVID-19 Patients

Unknown
NCT04445207

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

Unknown
NCT04434131Phase 2

Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19

Completed
NCT04363034

Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program

Unknown
NCT04884477

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

Completed
NCT04364737Phase 2

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

Completed
NCT04408040Phase 2

Use of Convalescent Plasma for COVID-19

Terminated
NCT05578391Phase 2

Passive Immunotherapy In Patients With SARS CoV-2

Completed
NCT04472572

Expanded Access to Convalescent Plasma for Treatment of COVID-19

Unknown
NCT04539275Phase 3

VA CoronavirUs Research and Efficacy Studies-1

Terminated

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
67